全球新药研发格局及BD交易趋势

C I T E L I N E . C O M全球新药研发格局及BD交易趋势Shuhua Zhou （周淑华） Ph.DCiteline26thAug 2025About Norstella2Our Mission:Smoothing Access To Life Saving Therapies3Commercial IntelligenceInsurance Claims & Electronic Medical Records Analytics MMITUS Market AccessCombined Consulting & Custom Solutions Dedham GroupClinical IntelligenceUS Market Access & ReimbursementThe global drug R&D pipeline in 2025Outline0102Partnership trends03Outlook in futureTotal Pipeline Size Has Grown by 4.6%23,875 Drugs under active developmentExpansion rate slightly lower▪ 2024 was up 7.2%1,050 more drugs in development▪ 4,546 new drugs identified and addedNew drug statistics▪ 38.8% were anticancers▪ 13.8% neurologicalsNovartis added the most new candidates▪ 38 added, Jiangsu Hengrui added 36China closes the gap▪ 1,683 new drugs in US development▪ 1,495 new drugs in Chinese development3Breakdown of The Pipeline by PhaseGrowth at all clinical stages▪ Phase I up by 6.8%▪ Phase II up by 6.3%▪ Phase III up by 8.8%Preclinical up by 1.8%▪ Lower than 2024’s 5.5%20R&D Pipeline by Therapeutic Area2025 vs 2024Oncology remains the biggest TA▪ 9,746 drugs in 2025▪ Expansion of 3.7% from 2024, lower thanthe global pipeline expansion rate▪ 39.7% of all drugs, down from 40.1%Neurological also below theaverage▪ 4.2% growth rate from 2024 to 2025Alimentary/metabolic stalled, aftera 13.1% growth rate in 2024Anti-infective R&D actuallydeclined▪ Pipeline size fell by 2.4%22▪ Pfizer returns to the top spot▪ Swiss rivals Roche and Novartis follow▪ Sanofi makes biggest jump within Top 10▪ Jiangsu Hengrui Pharmaceuticals falls outof the Top 10 after its landmark debut lastyear▪ But further advances from other Chinesecompanies, and strong Japanesepresence too▪ Top 10 companies contributed 5.4% of alldrugs, Top 25 10.0%. 19.4% comes fromcompanies with just 1 or 2 drugsPharmaprojects, Jan 202523Top 25 Companies by Pipeline SizeDisease Focus Areas of The Top 10Pharma CompaniesPharmaprojects, Jan 202524Cancer remains the top focus▪ BMS has the largest cancer portfolio, with144 of its drugs being oncology-focused▪ There are now 3 Top 10 companies whichdon’t have oncology as their primary areaBig pharma maintains diverseportfolios▪ GSK exhibits strong preference for anti-infectives▪ Eli Lilly goes for alimentary/metabolics▪ 5/10 companies have drugs in developmentin all 14 TAs, 5/10 do not include hormonalproducts or antiparasitics▪ Overall, signs of divergence in Topcompanies’focusesBreast cancer remains on top▪ Big 9.5% pipeline size increaseLead over NSCLC in 2ndmaintained▪ 10.0% pipeline expansionEntire Top 6 all cancer indications▪ Prostate cancer replaces brain cancerType 2 diabetes returns to Top 10 diseases▪ 12.8% pipeline increase8 of the Top 10 are still cancer indicationsNon-cancer indications▪ Coronavirus drops to out of Top 10▪ Alzheimer’s remains the only other non-oncology disease inthe Top 10▪ 43.3% increase in the R&D of drugs treating obesity, as theWegovy/Mounjaro effect escalatesPharmaprojects